A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.
An over-the-counter drug used to treat diarrhea combined with minocycline, an antibiotic used to treat bacterial infections, could one day change the lives of those living with cystic fibrosis.
Transplanting cells from healthy adult livers may work in treating a genetic liver-lung disorder that affects millions of people worldwide, according to an animal study in the April 18 online edition of the Journal of Clinical Investigation. Jayanta Roy-Chowdhury, M.D., professor of medicine and of genetics at Albert Einstein College of Medicine of Yeshiva University, is the study’s senior author.
A discovery by Johns Hopkins scientists about how a single-celled fungus survives in low-oxygen settings may someday help humans whose immune systems are compromised by organ transplants or AIDS.
U-M doctors stress a balanced approach, but note older therapies can offset risks, costs of ‘biologics’.
Many of the newest weapons in the war on cancer come in the form of personalized therapies that can target specific changes in an individual’s tumor. By disrupting molecular processes in tumor cells, these drugs can keep the tumor from growing and spreading. At the forefront of this work are Binghamton University researchers, Susan Bane, and Susannah Gal, who are deploying a new tool in their study of an enzyme called tubulin tyrosine ligase, or TTL.
A natural hormone known to inhibit aging can also protect kidneys against renal fibrosis, UT Southwestern Medical Center researchers have demonstrated.
On Wednesday, May 4, as part of Perimeter Institute’s Public Lecture Series presented by Sun Life Financial, Dr. Leroy Hood, a pioneer in systems approaches to biology and medicine, will discuss emerging technologies that may transform medical research over the next decade.
The HIV Vaccine Trials Network plans to clinically test a novel vaccine product developed by GeoVax scientists that expresses human granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with inactivated HIV proteins.
The meaning of the standard fecal coliform test used to monitor water quality has been called into question by a new study that identified sources of Escherichia coli bacteria that might not indicate an environmental hazard.
A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis (IPF).
For the first time in millions of years, king crabs are invading Antarctica which could mean organisms with disease-fighting compounds may be wiped out.
A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression of vision loss for this disease. The results highlight the benefit of the use of a neurotrophic factor to treat GA and provide hope to nearly one million Americans suffering from GA.
Rensselaer Polytechnic Institute Professor Marc-Olivier Coppens has developed a new technique for boosting the stability of enzymes, making them useful under a much broader range of conditions. Coppens confined lysozyme and other enzymes inside carefully engineered nanoscale holes, or nanopores. Instead of denaturing, these embedded enzymes mostly retained their 3-D structure and exhibited a significant increase in activity.
A team of scientists from Columbia University, Georgia Institute of Technology and the University of Granada in Spain have successfully reconstructed active enzymes from four-billion-year-old extinct organisms. By measuring the properties of these enzymes, they could examine the conditions in which the extinct organisms lived. The results shed new light on how life has adapted to changes in the environment from ancient to modern Earth.
Scientists from the Morgridge Institute for Research, the University of Wisconsin-Madison, the University of California and the WiCell Research Institute moved gene therapy one step closer to clinical reality by determining that the process of correcting a genetic defect does not substantially increase the number of potentially cancer-causing mutations in induced pluripotent stem cells.
Johns Hopkins scientists and their colleagues paired laboratory and epidemiologic data to find that men using the cardiac drug, digoxin, had a 24 percent lower risk for prostate cancer. The scientists say further research about the discovery may lead to use of the drug, or new ones that work the same way, to treat the cancer.
A section of the AIDS virus's protein envelope once considered an improbable target for a vaccine now appears to be one of the most promising, new research by Dana-Farber Cancer Institute scientists indicates.
Biologists at UC San Diego have identified the molecular mechanisms triggered by starvation in fruit flies that enhance the nervous system’s response to smell, allowing these insects and presumably vertebrates—including humans—to become more efficient and voracious foragers when hungry. Their discovery of the neural changes that control odor-driven food searches in flies, which they detail in a paper in the April 1 issue of the journal Cell, could provide a new way to potentially regulate human appetite.
Researchers at Weill Cornell Medical College have shown that it is possible to immunize mammals to control fertility. They say their technique could possibly be used on other mammals -- including humans -- because fertility hormones and their receptors are species-non-specific and are similar in both females and males. For pets, the technique could be an alternative to castration and adverse effects of hormone administration.
Giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers a wealth of other benefits, say a team of researchers led by Thomas Jefferson University. Their report is published in the March 31st issue of The New England Journal of Medicine (NEJM).
Basic Yellow 1, a dye used in neuroscience labs around the world, is a wonder drug for nematode worms. Thioflavin T extended lifespan in healthy worms by more than 50 percent and slowed the disease process in worms bred to mimic aspects of Alzheimer’s. The research could open new ways to intervene in aging and age-related disease.
Two biomedical engineering students from Ryerson University invent prosthetic arm that is controlled by brain signals and powered by pneumatics.
Unlike other drugs that target cancer cells from the outside with minimal effect, this “transport vehicle” carries multiple drugs that spare healthy cells, accumulate in tumor cells and strike cancer-specific molecular targets inside.
A new study showed that the drug AT-406 effectively targets proteins that block normal cell death from occurring. Blocking these proteins caused tumor cells to die, while not harming normal cells. The researchers believe the drug has potential to treat multiple types of cancer.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial.
University of Utah scientists used infrared light to make heart cells contract and inner-ear cells signal the brain. The discovery might improve cochlear implants for deafness and lead to devices to restore vision, maintain balance and treat movement disorders.
In the first time in more than a decade, the U-S Food and Drug administration gave the okay to a new cancer drug that is giving hope to patients with advanced melanoma. The disease is the most aggressive form of skin cancer. Until now, there were few treatment options for patients once melanoma spread to other areas of the body.
The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
Three CRI scientists describe in this latest issue of Science magazine immunity’s paradoxical role in the promotion and control of cancer, a new understanding that places new treatments like ipilimumab (Yervoy) and sipuleucel-T (Provenge) within the context of 100 years of progress in tumor immunology and cancer immunotherapy.
A first-of-its-kind study of gene therapy in the treatment of Parkinson’s disease determined that half of all patients who received the treatment had “clinically meaningful improvements” of their symptoms within six months of surgery, says study lead author and co-principal investigator Peter LeWitt, M.D.
SMA is Leading Genetic Cause of Infant and Toddler Mortality.
Clarkson University Physics Professor Igor Sokolov and his team have discovered a method of making the brightest ever synthesized fluorescent silica nanoparticles.
A few unassuming drops of liquid locked in a very precise game of “follow the leader” could one day be found in mobile phone cameras, medical imaging equipment, implantable drug delivery devices, and even implantable eye lenses. DARPA-funded study published in the peer-reviewed journal, Lab on a Chip.
In a step toward novel weight-loss therapies, Joslin Diabetes Center scientists identify cells in mice that can be triggered to transform into energy-burning brown fat.
An effort to increase biofuel production has led scientists to discover genes in yeast that improve their tolerance to ethanol, allowing the production of more ethanol from the same amount of nutrients. This study shows how genetically altered yeast cells survive higher ethanol concentrations, addressing a bottleneck in the production of ethanol from cellulosic material (nonfood plant sources) in quantities that could compete economically with fossil fuels.
The performance of a brain-machine interface designed to help paralyzed subjects move objects with their thoughts is improved with the addition of a robotic arm providing sensory feedback, a new study from the University of Chicago finds.
Pankaj Karande, a Rensselaer Polytechnic Institute assistant professor of chemical and biological engineering, is among a new generation of scientists and engineers developing exciting and novel new techniques to treat some of the most complex brain illnesses, including Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and brain cancer. His research has already attracted the interest of the Goldhirsh Foundation and now has garnered the support of the Alzheimer’s Association with an additional $80,000 in research funding.
As Rose Pharmaceuticals marks its first anniversary this month, the stockbroker and University at Buffalo researchers who founded the company are celebrating a year of accomplishments.
The University of Texas Health Science Center at Houston (UTHealth) and BioHouston, Inc. on Oct. 21 announced a new agreement to boost services to biomedical entrepreneurs and new bio-tech start-ups in Houston.
The Center for Biotechnology at SBU has organized a summit that will bring some of the world’s top bioscience companies together with entrepreneurs and academic innovators to explore the next generation of biomedical solutions.
Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN® in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer.
Researchers at the University of California, San Diego School of Medicine have discovered that a kind of sugar molecule common to chimpanzees, gorillas and other mammals but not found in humans provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.
A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.
Cancer uses devious means to evade treatment and survive. One prime example is the way tumors express anti-cell death (anti-apoptotic) proteins to resist chemotherapy and radiation. However, the Pellecchia laboratory at Sanford-Burnham Medical Research Institute has made two recent discoveries that may help curb these anti-apoptotic proteins and make current treatments more effective.
Some say the world's population will swell to 9 billion people by 2030 and that will present significant challenges for agriculture to provide enough food to meet demand, says University of Idaho animal scientist Rod Hill. Hill and Larry Branen, a University of Idaho food scientist, organized a symposium during the American Association for the Advancement of Science annual meeting Sunday to explore ways biotechnology could provide healthy and plentiful animal-based foods to meet future demands.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right